GeoVax Labs (NASDAQ:GOVX) Posts Quarterly Earnings Results, Beats Expectations By $0.49 EPS

GeoVax Labs (NASDAQ:GOVX) released its quarterly earnings results on Thursday. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.49, Zacks reports.

GeoVax Labs Price Performance

Shares of NASDAQ:GOVX traded down $0.10 during trading on Thursday, reaching $1.27. The company had a trading volume of 351,985 shares, compared to its average volume of 628,015. The company has a fifty day moving average of $1.71 and a two-hundred day moving average of $2.17. GeoVax Labs has a 12 month low of $1.09 and a 12 month high of $11.18.

Analyst Ratings Changes

Separately, D. Boral Capital restated a “buy” rating and issued a $18.00 target price on shares of GeoVax Labs in a research note on Thursday, February 27th. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $14.20.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.